Alkermes plc (ALKS)

IE — Healthcare Sector
Peers: PTCT  KRYS  PCVX  TGTX  MTSR  ARWR  ACLX  PTGX  ACAD  NUVL 

Automate Your Wheel Strategy on ALKS

With Tiblio's Option Bot, you can configure your own wheel strategy including ALKS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ALKS
  • Rev/Share 9.1253
  • Book/Share 9.8484
  • PB 3.1967
  • Debt/Equity 0.0447
  • CurrentRatio 3.232
  • ROIC 0.1803

 

  • MktCap 5197067474.0
  • FreeCF/Share 2.9089
  • PFCF 10.8308
  • PE 14.9042
  • Debt/Assets 0.0323
  • DivYield 0
  • ROE 0.2365

 

  • Rating A
  • Score 4
  • Recommendation Buy
  • P/E Score 3
  • DCF Score 4
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade ALKS RBC Capital Mkts Sector Perform Outperform -- $44 Sept. 26, 2025
Initiation ALKS Wells Fargo -- Overweight -- $44 Sept. 3, 2025
Initiation ALKS Goldman -- Buy -- $43 July 15, 2025
Upgrade ALKS UBS Neutral Buy -- $42 June 17, 2025
Initiation ALKS Needham -- Buy -- $45 May 28, 2025
Initiation ALKS RBC Capital Mkts -- Sector Perform -- $40 March 13, 2025
Upgrade ALKS UBS Sell Neutral $21 $38 March 4, 2025
Initiation ALKS Deutsche Bank -- Buy -- $40 Feb. 11, 2025

News

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
ALKS
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral

— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — — ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN , Feb. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year …

Read More
image for news Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

About Alkermes plc (ALKS)

  • IPO Date 1991-07-16
  • Website https://www.alkermes.com
  • Industry Biotechnology
  • CEO Richard F. Pops
  • Employees 1800

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.